NASDAQ:ZIOP - ZIOPHARM Oncology Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $6.30
  • Forecasted Upside: 116.49 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$2.91
▼ -0.01 (-0.34%)
1 month | 3 months | 12 months
Get New ZIOPHARM Oncology Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ZIOP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ZIOP

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$6.30
▲ +116.49% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for ZIOPHARM Oncology in the last 3 months. The average price target is $6.30, with a high forecast of $7.50 and a low forecast of $5.50. The average price target represents a 116.49% upside from the last price of $2.91.
Buy
The current consensus among 5 investment analysts is to buy stock in ZIOPHARM Oncology. This rating has held steady since March 2019, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
6/9/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/7/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/6/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/5/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/3/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/1/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/31/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/30/2020

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/20/2020Raymond JamesReiterated RatingBuy$5.50High
i
11/6/2020Raymond JamesSet Price TargetOutperform$5.50Low
i
9/15/2020Raymond JamesSet Price TargetOutperform$5.50Low
i
8/7/2020Raymond JamesSet Price TargetOutperform$5.50Low
i
7/10/2020Raymond JamesSet Price TargetOutperform$5.50Low
i
6/21/2020LaidlawReiterated RatingBuy$7.50High
i
6/21/2020Cantor FitzgeraldReiterated RatingOverweight ➝ Market Perform$6.00High
i
Rating by A. Young at Cantor Fitzgerald
6/19/2020Jefferies Financial GroupInitiated CoverageBuy$7.00High
i
6/8/2020Cantor FitzgeraldReiterated RatingOverweightMedium
i
Rating by A. Young at Cantor Fitzgerald
5/28/2020Raymond JamesSet Price TargetOutperform$5.50High
i
5/11/2020HC WainwrightReiterated RatingBuy$6.50 ➝ $5.50High
i
Rating by Swayampakula Ramakanth at HC Wainwright
5/8/2020Raymond JamesSet Price TargetOutperform$5.50Low
i
3/3/2020Cantor FitzgeraldInitiated CoverageOverweight$6.00High
i
3/3/2020HC WainwrightReiterated RatingBuy$6.50Low
i
3/3/2020Raymond JamesLower Price TargetOutperform$6.50 ➝ $5.50High
i
1/17/2020Raymond JamesSet Price TargetOutperform$6.50High
i
Rating by David Novak at Raymond James
12/10/2019Raymond JamesSet Price TargetOutperform$6.50Low
i
Rating by David Novak at Raymond James
12/10/2019HC WainwrightReiterated RatingBuy$6.50High
i
11/25/2019Raymond JamesSet Price TargetOutperform$6.50High
i
Rating by David Novak at Raymond James
11/8/2019Raymond JamesSet Price TargetOutperform$6.50High
i
Rating by David Novak at Raymond James
10/29/2019Raymond JamesReiterated RatingOutperform$6.50Low
i
Rating by David Novak at Raymond James
10/2/2019Raymond JamesSet Price TargetOutperform$6.50Low
i
Rating by David Novak at Raymond James
10/2/2019HC WainwrightReiterated RatingBuy$6.50Low
i
8/22/2019Raymond JamesInitiated CoverageOutperform$6.50High
i
5/9/2019HC WainwrightReiterated RatingBuy$5.50Medium
i
Rating by Swayampakula Ramakanth at HC Wainwright
4/4/2019Lake Street CapitalInitiated CoverageBuy ➝ Buy$7.00Medium
i
4/1/2019LaidlawInitiated CoverageBuy ➝ Buy$7.50High
i
11/15/2018Raymond JamesUpgradeMarket Perform ➝ Outperform$5.00Medium
i
11/13/2018HC WainwrightSet Price TargetBuy$6.00High
i
Rating by Swayampakula Ramakanth at HC Wainwright
6/18/2018JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightLow
i
5/14/2018HC WainwrightReiterated RatingBuy$5.50Low
i
Rating by Swayampakula Ramakanth at HC Wainwright
3/5/2018HC WainwrightSet Price TargetBuy$10.00High
i
Rating by Swayampakula Ramakanth at HC Wainwright
12/14/2017HC WainwrightSet Price TargetBuy$10.00Medium
i
Rating by Swayampakula Ramakanth at HC Wainwright
12/11/2017Raymond JamesReiterated RatingHoldHigh
i
Rating by Reni Benjamin at Raymond James
11/7/2017HC WainwrightReiterated RatingBuy$9.50N/A
i
Rating by Swayampakula Ramakanth at HC Wainwright
8/1/2017HC WainwrightSet Price TargetBuy$10.00Medium
i
Rating by Swayampakula Ramakanth at HC Wainwright
6/1/2017HC WainwrightInitiated CoverageBuy ➝ Buy$9.50High
i
Rating by S. Ramakanth at HC Wainwright
2/28/2017Griffin SecuritiesReiterated RatingBuy$23.00N/A
i
2/10/2017Griffin SecuritiesReiterated RatingBuy$21.00 ➝ $23.00N/A
i
1/12/2017JPMorgan Chase & Co.Reiterated RatingHoldN/A
i
11/19/2016Griffin SecuritiesReiterated RatingBuy$21.00N/A
i
Rating by Keith Markey at Griffin Securities
8/15/2016Griffin SecuritiesReiterated RatingBuy$21.00N/A
i
Rating by Keith Markey at Griffin Securities
8/10/2016Wells Fargo & CompanyUpgradeUnderperform ➝ Market PerformN/A
i
Rating by Jim Birchenough at Wells Fargo & Company
7/18/2016MizuhoReiterated RatingNeutral$7.00 ➝ $5.00N/A
i
7/15/2016Wells Fargo & CompanyReiterated RatingUnderperformN/A
i
Rating by Jim Birchenough at Wells Fargo & Company
7/1/2016Griffin SecuritiesReiterated RatingBuy$21.00N/A
i
Rating by Keith Markey at Griffin Securities
6/8/2016Wells Fargo & CompanyReiterated RatingSellN/A
i
Rating by Jim Birchenough at Wells Fargo & Company
6/7/2016Griffin SecuritiesReiterated RatingBuy$21.00N/A
i
Rating by Keith Markey at Griffin Securities
6/2/2016Raymond JamesInitiated CoverageMarket PerformN/A
i
5/26/2016Griffin SecuritiesReiterated RatingBuy$21.00N/A
i
Rating by Keith Markey at Griffin Securities
5/19/2016Wells Fargo & CompanyReiterated RatingSellN/A
i
Rating by Jim Birchenough at Wells Fargo & Company
5/12/2016Wells Fargo & CompanyReiterated RatingSell$6.50N/A
i
Rating by Jim Birchenough at Wells Fargo & Company
5/11/2016MizuhoBoost Price TargetNeutral$6.00 ➝ $7.00N/A
i
1/25/2016MizuhoBoost Price TargetHold ➝ Neutral$6.00 ➝ $10.00N/A
i
1/22/2016Wells Fargo & CompanyReiterated RatingSellN/A
i
1/15/2016JPMorgan Chase & Co.Reiterated RatingHoldN/A
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
12/10/2015Griffin SecuritiesReiterated RatingBuy$21.00N/A
i
Rating by Keith Markey at Griffin Securities
12/3/2015Wells Fargo & CompanyInitiated CoverageUnderperformN/A
i
(Data available from 11/30/2015 forward)
ZIOPHARM Oncology logo
ZIOPHARM Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Sleeping Beauty (SB), which is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T-cells outside of the body for infusion; and Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to attack cancer cells. It is developing Ad-RTS-hIL-12 plus veledimex, which is in Phase 2 clinical trial, to treat patients with recurrent glioblastoma multiforme in adults. The company is also developing chimeric antigen receptor (CAR) T-cell and T-cell receptor T-cell therapies. ZIOPHARM Oncology, Inc. has license agreement with Precigen, Inc. and MD Anderson Cancer Center; collaboration with MD Anderson targeting CD19 on malignant B cells using Sleeping Beauty platform; and research and development agreement with the National Cancer Institute to evaluate autologous peripheral blood lymphocytes, and Ares Trading S.A. The company was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $2.91
$2.88
$3.00

50 Day Range

MA: $2.55
$2.09
$2.92

52 Week Range

Now: $2.91
$1.79
$5.61

Volume

1,001,400 shs

Average Volume

1,886,742 shs

Market Capitalization

$623.59 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.28